Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

Turning to Wall Street, the analysts’ consensus rating for Novavax is Hold, based on one Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NVAX stock price ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and Intuitive Surgical (ISRG – Research Repor ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...